Anuh Pharma Q4 FY26 Results: PAT Rs 12 Cr
- May 21, 2026
- Posted by: Kashish Aggarwal
- Category: News
Anuh Pharma Q4 FY26 results were declared on May 20, 2026. The company reported PAT of Rs 12 crore for the quarter ended March 31, 2026, down 0% YoY compared to Rs 12 crore in Q4 FY25. Revenue from operations stood at Rs 202 crore, up 2% YoY. Gross profit was Rs 17 crore (+6%). Results are on a Standalone basis. Anuh Pharma is a Pharmaceuticals and APIs company listed on Indian stock exchanges.
Click Here – Get Free Investment Predictions
Anuh Pharma Q4 FY26 Financial Highlights
| Metric | Q4 FY26 (Rs Cr) | Q4 FY25 (Rs Cr) | YoY Change |
|---|---|---|---|
| Revenue | 202 | 198 | +2% |
| Gross Profit | 17 | 16 | +6% |
| Net Profit | 12 | 12 | +0% |
| Basis | Standalone | ||
Note: Anuh Pharma Q4 FY26 results declared May 20, 2026. Verify from BSE/NSE audited filings before making investment decisions.
Anuh Pharma Q4 FY26 Performance Analysis
The Anuh Pharma Q4 FY26 results reflect the company’s performance in the January to March 2026 quarter. The quarter demonstrates stable operational delivery. Anuh Pharma operates in the Pharmaceuticals and APIs sector, a segment supported by India’s GDP growth above 6.5% and domestic demand momentum in FY26.
Revenue growth of 2% YoY to Rs 202 crore demonstrates continued business momentum for Anuh Pharma in Q4 FY26.
Screen the best stocks on the Univest Screener.
Key Factors Driving Anuh Pharma Q4 FY26 Results
Revenue Performance
Anuh Pharma Q4 FY26 revenue of Rs 202 crore was up 2% YoY. Revenue momentum reflects steady demand conditions in the Pharmaceuticals and APIs sector.
Profitability and Margins
The Anuh Pharma Q4 FY26 PAT of Rs 12 crore (down 0% YoY) reflects stable earnings delivery in a competitive environment.
India Macro Tailwinds Q4 FY26
The January to March 2026 quarter was supported by India’s robust macroeconomic environment with GDP above 6.5%, government capex continuity at Rs 11.21 lakh crore in the Union Budget FY27, and strong domestic consumption. The Reserve Bank of India’s accommodative policy stance supported credit and demand conditions. For Anuh Pharma, operating in the Pharmaceuticals and APIs sector, these macro conditions provided a constructive backdrop during the quarter ended March 31, 2026.
FY27 Outlook
Following Anuh Pharma Q4 FY26 results, investor focus will shift to FY27 revenue guidance, margin improvement roadmap, capital allocation plans, and management commentary on demand visibility. The Pharmaceuticals and APIs sector continues to benefit from India’s structural growth, rising consumption, and investment cycle. Sustaining the growth momentum and expanding margins will be the key priorities for management in FY27.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Frequently Asked Questions on Anuh Pharma Q4 FY26
What is Anuh Pharma Q4 FY26 net profit?
Ans. Anuh Pharma Q4 FY26 PAT of Rs 12 crore, down 0% YoY from Rs 12 crore in Q4 FY25. Results declared May 20, 2026 on a Standalone basis.
What is Anuh Pharma Q4 FY26 revenue?
Ans. Anuh Pharma Q4 FY26 revenue was Rs 202 crore, up 2% YoY. Gross profit was Rs 17 crore (+6%).
When were Anuh Pharma Q4 FY26 results declared?
Ans. Anuh Pharma Q4 FY26 results were declared on May 20, 2026, at the board of directors meeting approving audited financial statements for Q4 and full-year FY26.
Is Anuh Pharma a good investment after Q4 FY26 results?
Ans. Investment decisions require individual assessment of fundamentals, valuation, and risk tolerance. This article is for educational purposes. Consult a SEBI-registered financial advisor before investing in Anuh Pharma.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.
